Navigation Links
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

Halozyme. "We look forward to the study investigators presenting the updated study results at the poster session and ensuing discussion."

Based on the magnitude of response and safety observed in the Phase 1b study, Halozyme announced in April the initiation of a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer. Approximately 124 patients will participate in the study and receive gemcitabine and nab-paclitaxel either with or without PEGPH20. Secondary endpoints of the trial include clinical evaluation of patient response in both treatment arms by tumor biopsy hyaluronan (HA) status.

Halozyme is also developing a HA diagnostic tool that will help evaluate potential treatment benefit based on HA levels for use in the randomized Phase 2 trial. Clinically validating this HA-diagnostic approach in the pancreatic cancer trial may also provide proof-of-concept for use of PEGPH20 in other HA-rich tumor types.

Halozyme Abstracts at ASCO:

  • Poster Presentation/Discussion: (E Hall D1): "A Phase 1b Study of Gemcitabine Plus PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in Patients with Stage IV Previously Untreated Pancreatic Cancer" will be presented by Sunil R. Hingorani M.D ., Ph.D., Fred Hutchinson Cancer Research Center on Monday, June 3 at 1:15PM-5:15PM CDT; discussion from 4:45 PM-5:45PM CDT. (Abstract #4010)
  • Educational Book Abstract: "Pharmacokinetic (PK)/Pharmacodynamic (PD) Results From a Phase 1b Study of PEGylated Hyaluronidase PH20 (PEGPH20) in Combination with Gemcitabine (Gem) in Patients with Pancreatic Cancer" (Abstract # e15005)

*33 percent response rate reported in the ASCO abstract based on partial data available at the time of abstract submission.

About Pancreatic Cancer
In most patients diagnosed with metastat
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Washington D.C. (PRWEB) September 22, 2014 ... and Georgetown President John DeGioia on Friday renewed ... understanding for an additional five years to expand ... security, biosecurity, nonproliferation and global climate, energy and ... expansion of an MOU originally signed in December ...
(Date:9/22/2014)... 2014 Topical BioMedics, Inc., is celebrating ... end their suffering, restoring hope an quality of life ... only possible because of the innovative cellular biomedicines research ... a reality. , The company was founded in ... Paradise (president, chief of research, and Topricin inventor), Aurora ...
(Date:9/22/2014)... DUBLIN , Sept. 22, 2014 ... the "Global and Chinese Microcrystalline Cellulose Industry Report ... The Global and Chinese Microcrystalline Cellulose Industry Report 2014 ... state of the global microcrystalline cellulose industry with a ... provides a basic overview of the industry including definitions, ...
(Date:9/22/2014)... -- Neogen Corporation (Nasdaq: NEOG ) announced today ... 2015 fiscal year, which ended Aug. 31, was $8,883,000 ... $7,839,000 in the first quarter of last year. Adjusted ... earnings per share in the current quarter were $0.24, ... quarter revenues increased 15% to $67,599,000, from the previous ...
Breaking Biology Technology:Lawrence Livermore Renews Pact with Georgetown University to Expand Research and Education in Science and Policy 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7
... SILVER SPRING, Md., May 9, 2011 The U.S. Food ... the public relating to the development of a user ... applications.   (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... such as a microorganism, plant, or animal cell, while ...
... May 9, 2011 On May 17-18, 2011, ... created to support, mentor, and develop minority-, woman-, ... host its fourth annual networking conference and EXPO ... the Renaissance Newark Airport Hotel in Newark, N.J. ...
... Biosciences, Inc. (Nasdaq: RDEA ), a biotechnology ... the treatment of serious diseases, today reported recent accomplishments ... "Results from our recently completed Phase 2b ... potential to bring relief to millions of patients currently ...
Cached Biology Technology:FDA Requests Input on Development of User Fee Program for Biosimilar and Interchangeable Biological Products 2Diversity Alliance for Science to Host Fourth Annual Networking Conference and Expo 2Diversity Alliance for Science to Host Fourth Annual Networking Conference and Expo 3Diversity Alliance for Science to Host Fourth Annual Networking Conference and Expo 4Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 6
(Date:9/22/2014)... Fla. In 2011 the Society of Environmental Toxicology ... experts to identify and prioritize the scientific research needed ... products (PPCPs) in the environment. The effort was ... issue of the Society,s international journal, Integrated Environmental ... is accompanied by a podcast interviewing the lead author ...
(Date:9/22/2014)... captured in this image burn in Khabarovsk Krai, a territory ... red hotspots, accompanied by plumes of smoke mark active fires. ... the east towards the Sea of Okhotsk. Taiga ... swampy forest inhabit the central depression, and deciduous forests are ... are common in Russia in the summer, the 2014 wildfire ...
(Date:9/22/2014)... in the wake of the huge King Fire blazing ... The King Fire is burning in steep terrain in ... Creek Canyon, and the Rubicon Canyon, north of the ... Placer County and burned onto the Tahoe National Forest ... is expected to be minimal on Sept. 22 due ...
Breaking Biology News(10 mins):Priorities for research on pharmaceutical and personal care products in the environment 2
... MARC (Minority Access to Research Careers) Program has announced ... Immunologists (AAI) Advanced Course in Immunology at The University ... 5, 2011. These awards are meant to promote ... into the mainstream of the basic science community and ...
... with the discovery that the tiny 3 mm long marine ... buoyancy control as whales. Reporting this week in the ... Survey describe how Southern Ocean copepods a crustacean rich ... winter when seas are stormy and food scarce. To reach ...
... like something out of a comic book or a science ... exactly what two investigators at the Wellman Center for Photomedicine ... that will appear in the journal Nature Photonics ... PhD, and Seok Hyun Yun, PhD, describe how a single ...
Cached Biology News:Single GFP-expressing cell is basis of living laser device 2Single GFP-expressing cell is basis of living laser device 3
... enzyme-activity assay based on measurenment of enzyme ... antibody coated microtiter plate. The procedure includes ... or controls, 2nd enzyme reaction) separated ... intended for the determination of human enzymaticaly ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
... A modified nucleotide structure called a ... of most naturally-occurring eukaryotic mRNAs and ... Analog for a portion of the ... transcription reaction results in the synthesis ...
Biology Products: